Patents for A61P 35 - Antineoplastic agents (221,099)
07/2002
07/18/2002WO2002055087A1 Dihydro-triterpenes in the treatment of viral infections, cardiovascular disease, inflammation, hypersensitivity or pain
07/18/2002WO2002055075A2 Compounds and methods for regulating cell differentiation
07/18/2002WO2002055067A2 Fumaric acid derivatives as nf-kappab inhibitors
07/18/2002WO2002055066A1 Fumaric acid derivatives as nf-kappa-b inhibitors
07/18/2002WO2002055063A2 Fumaric acid amides
07/18/2002WO2002054933A2 Method for photodynamic therapy and applicator for carrying out said therapy
07/18/2002WO2002054851A2 Inhibition of pathological angiogenesis in vivo
07/18/2002WO2002048349A8 Polypeptide capable of binding to heparin
07/18/2002WO2002034205A3 Using heat shock proteins to increase immune response
07/18/2002WO2002034202A3 Multi-component antioxidant compounds, pharmaceutical compositions containing same and their use for reducing or preventing oxidative stress
07/18/2002WO2002030458A8 Yersinia adhesion protein as vaccine adjuvant
07/18/2002WO2002029088A3 Highly expressible genes
07/18/2002WO2002028418B1 Methods of modulating apoptosis by administration of relaxin agonists or antagonists
07/18/2002WO2002028414B1 Compositions and methods for wt1 specific immunotherapy
07/18/2002WO2002022558A3 2-amino-2-alkyl-3 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
07/18/2002WO2002022159A8 Thionin as an antineoplastic and immunostimulant
07/18/2002WO2002016310A9 Selective androgen receptor modulators and methods of use thereof
07/18/2002WO2002013758A3 System for regulating in vivo the expression of a transgene by conditional inhibition
07/18/2002WO2002011704A3 Use of aryl-substituted 1,1-diphosphonates for the treatment of bone diseases
07/18/2002WO2002009680A3 Pharmacologically active substance for treating cardiovascular disorders
07/18/2002WO2002007722A3 Valproic acid and derivatives thereof as histone deacetylase inhibitors
07/18/2002WO2002005827A3 Use of natural products in cancer treatment
07/18/2002WO2002004516A3 Use of the heat shock protein gp96
07/18/2002WO2002003912A3 Novel c-4 substituted retinoids
07/18/2002WO2002002633A3 Transporters and ion channels
07/18/2002WO2002002556A3 AZA-BRIDGED-BICYCLIC AMINO ACID DERIVATIVES AS α4 INTEGRIN ANTAGONISTS
07/18/2002WO2002002143A3 Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
07/18/2002WO2001096299A3 Indole derivatives and their use as 15-lipoxygenase inhibitors
07/18/2002WO2001095936A3 Monoterpenes and sesquiterpenes as radiation sensitizers
07/18/2002WO2001094391A3 Intracellular signaling proteins
07/18/2002WO2001090103A3 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as protein kinase modulators
07/18/2002WO2001089499A3 Use of pyridinylimidazole carbamate derivate for the manufacture of a medicament for the treatment of cancer
07/18/2002WO2001085798A3 Human monoclonal antibodies to dendritic cells
07/18/2002WO2001085790A3 Mammalian cytokine receptor subunit proteins, related reagents and methods
07/18/2002WO2001083525A3 Modified peptides, comprising an fc domain, as therapeutic agents
07/18/2002WO2001081590A3 Protein phosphatases
07/18/2002WO2001081586A3 21657, a human short-chain dehydrogenase and uses thereof
07/18/2002WO2001081377A3 Integrin/adhesion antagonists
07/18/2002WO2001079468A3 Drug metabolizing enzymes
07/18/2002WO2001079282A3 Molecules associated with human reproduction
07/18/2002WO2001078789A3 Poliovirus replicons encoding therapeutic agents and uses thereof
07/18/2002WO2001072822A3 Genes involved in intestinal inflammatory diseases and use thereof
07/18/2002WO2001072728A3 Novel piperazine derivatives
07/18/2002WO2001072685A3 Polyamine analogues as cytotoxic agents
07/18/2002WO2001068142A9 Therapeutic and diagnostic ligand systems comprising transport molecule binding properties and medicaments containing the same
07/18/2002WO2001066747A3 Proteins named fctrx and nucleic acids encoding same
07/18/2002WO2001062920A3 Compositions and methods for diagnosis and therapy of malignant mesothelioma
07/18/2002WO2001060370A1 Remedies for endothelin-induced diseases
07/18/2002WO2001056547A3 Preparation of aqueous clear solution dosage forms with bile acids
07/18/2002WO2001049295A9 Use of low dosage bisphosphonates to inhibit cardiac and arterial calcification
07/18/2002WO2001005834A9 Human tumor necrosis factor receptors tr13 and tr14
07/18/2002US20020095036 Synthesis of temozolomide and analogs
07/18/2002US20020095033 Monocyclic L-nucleosides, analogs and uses thereof
07/18/2002US20020095024 B7-related nucleic acids and polypeptides useful for immunomodulation
07/18/2002US20020094994 Pyrrolidine carboxylic Acid or ester derivatives are useful for treating alpha 4 beta 1 mediated cell adhesion
07/18/2002US20020094987 Amide or thioamide substituted benzimidazole or quinoxaline derivatives; therapeutic utility via inhibition of tumor necrosis factor or phosphodiesterase
07/18/2002US20020094983 Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
07/18/2002US20020094980 Preparing 1,1-dioxo-2-phenyl-3-carboxy-4-phenyl-1,2-benzo(e)-thiazines by a five-step process starting with a (2-(methyl-oxycarbonyl-)phenyl-sulfonamido-)benzene; alkylation; cyclization; hydroxylation; esterification and coupling
07/18/2002US20020094955 Plasminogen-like polynucleotides, polypeptides, and antibodies
07/18/2002US20020094350 Compositions containing an active fraction isolated from scutellariae barbatae and methods of use
07/18/2002US20020094339 Methods for treating mammary gland disorders
07/18/2002US20020094326 Treating tissue with phosphodiesterase inhibitor compound and administering exogenous nucleic acid
07/18/2002US20020094323 Administration of reactive oxygen species inhibitor or scavenger and at least one monocyte maturation-promoting agent
07/18/2002US20020092539 Hair clip
07/18/2002DE10102050A1 Food, nutritional supplement, feed or medicament preparations containing conjugated cis/trans-octatrienoic acid, useful e.g. for reducing food intake, improving food utilization or treating cancer or diabetes
07/18/2002DE10102048A1 Use of active antithrombin III having endothelial cell proliferation inhibitory activity for combating diseases associated with angiogenesis, e.g. retinopathy, neuropathy, leprosy and cancer
07/18/2002DE10100280A1 DNA-Sequenzen, codierend für ein Apoptose-Signaltransduktionsprotein DNA sequences encoding an apoptosis-Signaltransduktionsprotein
07/18/2002DE10059631A1 T-Zellepitope des Papillomavirus L1-und E7-Proteins und ihre Verwendung in Diagnostik und Therapie T cell epitopes of the papillomavirus L1 and E7 protein and their use in diagnostics and therapy
07/18/2002CA2776023A1 Fumaric acid amides
07/18/2002CA2436876A1 Transcriptional mediators of blood vessel development and endothelial differentiation
07/18/2002CA2434793A1 Ancillary composition for the preparation of committed mature dendritic cells
07/18/2002CA2434672A1 Sfrp and peptide motifs that interact with sfrp and methods of their use
07/18/2002CA2434543A1 Inhibition of pathological angiogenesis in vivo
07/18/2002CA2434399A1 Method for processing dendritic cells and for activating macrophages with ru 41740
07/18/2002CA2434274A1 N-pyridyl carboxamide derivatives and pharmaceutical compositions containing them
07/18/2002CA2434269A1 Histone deacetylase inhibitors in diagnosis and treatment of thyroid neoplasms
07/18/2002CA2434044A1 1,2-disubstituted cyclic inhibitors of matrix metallorproteases and tnf-alpha
07/18/2002CA2434042A1 Asip-related proteins
07/18/2002CA2433981A1 Mikanolide derivatives, their preparation and therapeutic uses
07/18/2002CA2433960A1 1-dimercaptoalkylquinazolin-2,4(1h,3h)-diones as matrix metalloproteinase (mmp) inhibitors
07/18/2002CA2433742A1 Proteins and nucleic acids encoding same
07/18/2002CA2433740A1 Human glioma antigen and process for preparing the same
07/18/2002CA2433723A1 Chemical derivatives and their use as anti-telomerase agent
07/18/2002CA2433689A1 Process to concentrate insoluble proteins by vibrating membrane filtration
07/18/2002CA2433623A1 Pyridine derivatives useful as cyclooxygenase inhibitor
07/18/2002CA2432883A1 Antigenic ck-18 compounds for therapy and diagnosis and methods for using same
07/18/2002CA2432350A1 Method for inhibiting the expression of a target gene
07/18/2002CA2432341A1 Method for inhibiting the expression of a target gene and medicament for treating a tumor disease
07/18/2002CA2432114A1 4-(hetero)aryl substituted indolinones
07/18/2002CA2430794A1 Human genes and gene expression products isolated from human prostate
07/18/2002CA2430060A1 Diagnostic tumor markers, drug screening for tumorigenesis inhibition, and compositions and methods for treatment of cancer
07/18/2002CA2428497A1 Targeted modification of intracellular compounds
07/18/2002CA2428075A1 Fumaric acid derivatives as nf-kappab inhibitors
07/18/2002CA2427840A1 Methods of using imxp-888 and imxp-888 antagonists
07/18/2002CA2427146A1 Transcobalamin binding conjugates useful for treating abnormal cellular proliferation
07/18/2002CA2395711A1 Pharmaceutical compositions
07/17/2002EP1223176A2 Peptide mutant of human ERAB/HADH2, its X-ray crystal structure, and materials and method for identification of inhibitors thereof
07/17/2002EP1222928A2 Pharmaceutical compositions for treating or preventing cancer, especially melanoma
07/17/2002EP1222925A2 Kavalactone as TNF-alpha production inhibitor
07/17/2002EP1222924A1 Anticancer agents